Program
VIT-2763
Also written as “Vamifeport”, “Vamifeport (PR formulation)” and “Vamifeport IRF”.
Its studies are mostly in beta-Thalassemia · Hemochromatosis · Iron Overload · Anemia, Sickle Cell, led by CSL.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 71 open or running | phase 2since Apr 1, 2020 | Apr 1, 2020 | Apr 15, 2028phase 2 · NCT07332091 |
Also a collaborator on its studies: fortrea and labcorp-corporation-of-america-holdings-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 1, 2020First study: phase 2 study in beta-ThalassemiaFirst studyNCT04364269 · 35 enrolled · Greece, Israel, Italy and more
- Mar 23, 2021Phase 2 study in Anemia, Sickle CellNCT04817670 · 25 enrolled · United States, France, Greece and more
- Jun 16, 2021Phase 2 study in beta-ThalassemiaNCT04938635 · United States, Bulgaria, Israel
- Sep 20, 2021Phase 1 study in HealthyNCT05077436 · 28 enrolled · United Kingdom
- Dec 6, 2024Phase 1 study in Iron OverloadNCT06726863 · 22 enrolled · United Kingdom
- May 21, 2025Phase 1 study in Healthy VolunteersNCT06996184 · 28 enrolled · United Kingdom
- Jan 8, 2026Phase 2 study in HemochromatosisNCT07332091 · 84 enrolled · United States, Australia, Austria and more
Ahead
- Apr 15, 2028Primary completion: phase 2 study in HemochromatosisNCT07332091
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07332091Hemochromatosis · United States, Australia, Austria and more | 2 | Active, not recruiting | Apr 15, 2028 | 84 |
| NCT06996184Healthy Volunteers · United Kingdom | 1 | Completed | Jul 1, 2025 | 28 |
| NCT06726863Iron Overload · United Kingdom | 1 | Completed | Jan 27, 2025 | 22 |
| NCT05077436Healthy · United Kingdom | 1 | Completed | Dec 29, 2021 | 28 |
| NCT04938635beta-Thalassemia · United States, Bulgaria, Israel | 2 | Withdrawn | Jul 2023 | 0 |
| NCT04817670Anemia, Sickle Cell · United States, France, Greece and more | 2 | Completed | Mar 7, 2024 | 25 |
| NCT04364269beta-Thalassemia · Greece, Israel, Italy and more | 2 | Completed | Oct 11, 2021 | 35 |
How it is read
Names in the registry
- “Vamifeport”, 1 entry
- “Vamifeport (PR formulation)”, 1 entry
- “Vamifeport IRF”, 1 entry
- “Vamifeport PR1”, 1 entry
- “Vamifeport PR2”, 1 entry
Codes read as this program: CSL624.
Conditions, from the studies’ own filings
- beta-Thalassemia, 2 studies
- Hemochromatosis, 1 study
- Iron Overload, 1 study
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.